Publicaciones en colaboración con investigadores/as de Pfizer (United States) (14)

2023

  1. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL Surveillance trial

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 3, pp. 331-343

2020

  1. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis

    Current Therapeutic Research - Clinical and Experimental, Vol. 93

  2. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies

    ACR Open Rheumatology, Vol. 2, Núm. 10, pp. 543-554

2018

  1. Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment

    RMD Open, Vol. 4, Núm. 1

  2. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies

    Rheumatology and Therapy, Vol. 5, Núm. 2, pp. 567-582

  3. Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current european rheumatology practice

    Patient Preference and Adherence, Vol. 12, pp. 2007-2014

2016

  1. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: Results of two Phase 2 randomised controlled trials

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 430-442

  2. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 4, pp. 687-695

  3. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 6, pp. 1133-1138

2015

  1. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

    Arthritis Research and Therapy, Vol. 17, Núm. 1

2014

  1. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis

    Arthritis and Rheumatology, Vol. 66, Núm. 11, pp. 2924-2937

2012

  1. Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

    Arthritis and Rheumatism, Vol. 64, Núm. 8, pp. 2504-2517

  2. Variants within STAT genes reveal association with anticitrullinated protein antibody-negative rheumatoid arthritis in 2 European populations

    Journal of Rheumatology, Vol. 39, Núm. 8, pp. 1509-1516

2010

  1. Series "update on tuberculosis" edited by C. Lange, M. Raviglione, W.W. Yew and G.B. Migliori number 2 in this series: The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement

    European Respiratory Journal, Vol. 36, Núm. 5, pp. 1185-1206